Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

venetoclax 45Cyclophosphamide 43Specimen Handling 41Cytarabine 39fludarabine 31Biopsy 30Azacitidine 24Rituximab 20Methotrexate 17fludarabine phosphate 16blinatumomab 15Vincristine 15Dexamethasone 14Daunorubicin 14ibrutinib 13Prednisone 13Magnetic Resonance Spectroscopy 13Whole-Body Irradiation 12Injections 12obinutuzumab 11merphos 11Mercaptopurine 11Calcium Dobesilate 11Mycophenolic Acid 10Filgrastim 10Doxorubicin 10X-Rays 9Tacrolimus 9Leucovorin 9Etoposide 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interleukin-2 × Other hematologic neoplasm × 30 days × Clear all
NCT07591649 2026-05-19

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

Masonic Cancer Center, University of Minnesota

Phase 1/2 Recruiting
18 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡